Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive long-term data for Aclasta

Novartis reports positive long-term data for Aclasta

20th October 2010

Novartis has published new clinical data which demonstrates the long-term efficacy of Aclasta, its treatment for osteoporosis among postmenopausal women.

According to data from the study, which involved more than 1,200 patients, use of the once-yearly drug therapy led to improved preservation of bone mass among sufferers over a period of six years.

This meant that patients were less susceptible to the risk of spinal fractures compared to those who stopped treatment after three years.

The new data serves to reinforce the established safety and efficacy profile of Aclasta, which has been approved in around 90 countries and is administered more than a million times worldwide each year.

Novartis' global head of development Trevor Mundel said: "Aclasta is highly effective at protecting patients against osteoporotic fractures for a long period of time and its once-yearly dosing represents an important improvement for patients and doctors in terms of compliance."

Last month, the company published positive clinical trial findings from a study of SOM230, an investigational treatment for the hormone disorder Cushing's disease.ADNFCR-8000103-ID-800125854-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.